8-K: Akebia Therapeutics Launches Vafseo, Eyes Expansion into Non-Dialysis Market

Akebia Therapeutics has commenced the U.S. commercial launch of Vafseo for anemia in dialysis patients and is planning a Phase 3 trial for non-dialysis patients, while also advancing its pipeline.

Summary

• Akebia Therapeutics has launched Vafseo, a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis, with the first shipment occurring on January 9, 2025.
• The company has secured contracts covering nearly 100% of U.S. dialysis patients and has obtained Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement.
• Vafseo is an oral Hypoxia-Inducible Factor (HIF) inhibitor, offering a novel approach compared to the 30-year-old standard of care, erythropoiesis-stimulating agents (ESAs).
• Akebia is also pursuing label expansion for Vafseo to treat anemia in late-stage non-dialysis CKD patients, with a Phase 3 trial planned for mid-2025.
• The company estimates a $1 billion U.S. market opportunity in the dialysis patient population and a multi-billion-dollar opportunity in the non-dialysis market.
• Akebia expects its current cash resources and cash from operations to fund its operating plan for at least two years.
• The company is also advancing its pipeline with additional assets targeting high unmet medical needs, including AKB-9090, a novel HIF-PH inhibitor, with a planned Phase 1 trial.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the launch of Vafseo and expansion plans, but also acknowledges risks and safety concerns. The sentiment is cautiously optimistic.

Positives

• Vafseo offers a novel oral treatment option for anemia in dialysis patients, addressing an unmet need.
• The company has secured broad market access with contracts covering nearly 100% of U.S. dialysis patients.
• TDAPA reimbursement provides a financial advantage for Vafseo.
• The planned Phase 3 trial for non-dialysis patients opens up a significantly larger market opportunity.
• The company's cash runway is projected to last for at least two years.
• Akebia is actively developing a pipeline of novel HIF-PH inhibitors for other high unmet medical needs.
• Nephrologist feedback indicates most would consider prescribing Vafseo.

Negatives

• Vafseo carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
• The safety of Vafseo has not been established for the treatment of anemia due to CKD in adults not on dialysis.
• There is a risk of hepatotoxicity, hypertension, seizures, and gastrointestinal erosion associated with Vafseo use.
• The global PRO2TECT study missed its primary MACE endpoint, although a U.S. sub-analysis showed no increased risk.

Risks

• There are risks associated with the commercial availability of Vafseo, including potential demand, market acceptance, and reimbursement.
• The competitive landscape for Vafseo includes potential generic entrants.
• The company's ability to attract and retain qualified personnel is a risk.
• Decisions made by health authorities, such as the FDA, could impact regulatory filings.
• There are risks associated with manufacturing, supply chain, and quality matters.
• Early termination of any of Akebia's collaborations is a potential risk.
• The company acknowledges that there is no guarantee that its current operating plan will be achieved in the time frame anticipated.

Future Outlook

Akebia plans to expand the use of Vafseo into the non-dialysis market, advance its pipeline of HIF-based therapies, and continue to execute its commercial launch strategy. The company expects its current cash resources to fund operations for at least two years.

Management Comments

• John Butler, CEO, stated that the company is focused on bettering the lives of people impacted by kidney disease.
• Management believes they are positioned to succeed in the dialysis market and capitalize on the larger non-dialysis market opportunity.

Industry Context

The launch of Vafseo represents a significant development in the treatment of anemia in CKD patients, offering an alternative to the long-standing ESA treatments. The expansion into the non-dialysis market could significantly increase the company's market share and revenue. The development of novel HIF-PH inhibitors also aligns with the industry's focus on innovative therapies for unmet medical needs.

Comparison to Industry Standards

• The current standard of care for anemia in dialysis patients is erythropoiesis-stimulating agents (ESAs), which have been used for 30 years. Vafseo offers a novel oral alternative.
• The market for anemia treatments in dialysis is estimated at $1 billion in the U.S., with companies like Amgen and Johnson & Johnson being major players in the ESA market.
• The non-dialysis market for anemia treatment is significantly larger, with potential for Vafseo to compete with existing ESA treatments and other emerging therapies.
• Akebia's approach of using a HIF-PH inhibitor is similar to other companies developing similar drugs, such as FibroGen with Roxadustat, which has faced regulatory challenges in the U.S.
• The planned Phase 3 trial for non-dialysis patients is crucial for Vafseo to gain market share in this segment, similar to how other companies have conducted large-scale trials to demonstrate efficacy and safety.

Stakeholder Impact

• Shareholders: The launch of Vafseo and expansion plans are expected to positively impact the company's value.
• Employees: The company's growth and pipeline development may lead to new opportunities.
• Customers: Patients with anemia due to CKD will have a new treatment option.
• Suppliers: The company's commercial launch will increase demand for its products.
• Creditors: The company's financial stability is supported by its cash runway.

Next Steps

• Fully enroll the VOICE trial.
• Execute the U.S. commercial launch of Vafseo.
• Initiate the Phase 3 trial for Vafseo in non-dialysis patients in mid-2025.
• Advance the pipeline, including initiating the first in human trial for AKB-9090.

Key Dates

Keywords

Vafseo, vadadustat, anemia, chronic kidney disease, CKD, dialysis, HIF inhibitor, hypoxia-inducible factor, non-dialysis, AKB-9090, TDAPA, commercial launch, Phase 3 trial